Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20 th, 2025.
A live audio webcast of the presentation will be accessible from the 'Events' page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthesized psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).
Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Colliers publishes 2024 Global Sustainability Report
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ and TSX: CIGI) released its 2024 Global Sustainability Report , highlighting the firm's achievements and progress against targets established in 2021. The report also offers a first look at Colliers' refreshed sustainability strategy, Built to Last , which is based on an updated materiality assessment conducted in the first quarter of 2025. The strategy is designed to align Colliers' priorities with today's most pressing environmental, social, and governance challenges and opportunities, anchored around three core pillars: 'As a global provider of real estate, engineering and investment management services, we are in a unique position to help owner, investor and occupier clients realize their sustainability aspirations while driving the same positive impact for our own operations,' said Jay Hennick, Global Chairman & CEO of Colliers. 'I'm proud of our 2024 performance and remaining agile in our approach to what's next. I look forward to continuing our journey toward a more sustainable future though Built to Last.' Highlights from the 2024 report include: To support the next phase of our sustainability leadership, Tonya Lagrasta has been appointed Global Head of Sustainability at Colliers. A long-time sustainability leader and trusted advisor within our business, Tonya brings more than 20 years of experience across sectors including commercial real estate, retail, consumer goods, financial services, pharmaceuticals, and the public sector. In this role she will spearhead the implementation of Built to Last and drive integration of sustainability across Colliers. 'Sustainability is a reflection of our values in action, and a pathway to long-term resilience,' said Lagrasta. 'Built to Last reflects where we are today – and more importantly, where we're going. I'm energized by our people's passion and proud to help lead this next chapter of impact.' The full 2024 Global Sustainability Report is available at . About Colliers Colliers (NASDAQ, TSX: CIGI) is a global diversified professional services and investment management company. Operating through three industry-leading platforms – Real Estate Services, Engineering, and Investment Management – we have a proven business model, an enterprising culture, and a unique partnership philosophy that drives growth and value creation. For 30 years, Colliers has consistently delivered approximately 20% compound annual returns for shareholders, fueled by visionary leadership, significant inside ownership and substantial recurring earnings. With nearly $5.0 billion in annual revenues, a team of 23,000 professionals, and more than $100 billion in assets under management, Colliers remains committed to accelerating the success of our clients, investors, and people worldwide. Learn more at , X @Colliers or LinkedIn . Media Contact Andrea Cheung Senior Manager, Global Integrated Communications +1 416 324 6402
Yahoo
2 hours ago
- Yahoo
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article "Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial" reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, "Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation" describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, "A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier" reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: "It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. "The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. "We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases." Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: "These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation." About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030. View source version on Contacts EpiEndo Pharmaceuticals: Maria Bech, CEO+354 454 0090 Vigo Consulting (media relations):Rozi Morris+44 20 7390 0230epiendo@ Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Colliers publishes 2024 Global Sustainability Report
Launches refreshed sustainability strategy Built to Last TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ and TSX: CIGI) released its 2024 Global Sustainability Report, highlighting the firm's achievements and progress against targets established in 2021. The report also offers a first look at Colliers' refreshed sustainability strategy, Built to Last, which is based on an updated materiality assessment conducted in the first quarter of 2025. The strategy is designed to align Colliers' priorities with today's most pressing environmental, social, and governance challenges and opportunities, anchored around three core pillars: Environmental sustainability: Supporting decarbonization and climate resilience Workplace experience: Creating inclusive, healthy, high-performing spaces Ethical governance & practices: Embedding trust, transparency, and responsible innovation 'As a global provider of real estate, engineering and investment management services, we are in a unique position to help owner, investor and occupier clients realize their sustainability aspirations while driving the same positive impact for our own operations,' said Jay Hennick, Global Chairman & CEO of Colliers. 'I'm proud of our 2024 performance and remaining agile in our approach to what's next. I look forward to continuing our journey toward a more sustainable future though Built to Last.' Highlights from the 2024 report include: Achieved a 27.6% reduction in Scope 1 and 2 emissions per square foot from our 2021 baseline. Earned WELL Health-Safety Ratings in 87.4% of Colliers offices ≥ 2,500 sq. ft., up from 35% in 2022. Expanded our electric vehicle fleet to 170+, representing a 5x increase in just two years. Reached 88% participation in our global employee engagement survey, with scores exceeding external benchmarks. 68% of our Colliers Gives volunteering goal achieved. To support the next phase of our sustainability leadership, Tonya Lagrasta has been appointed Global Head of Sustainability at Colliers. A long-time sustainability leader and trusted advisor within our business, Tonya brings more than 20 years of experience across sectors including commercial real estate, retail, consumer goods, financial services, pharmaceuticals, and the public sector. In this role she will spearhead the implementation of Built to Last and drive integration of sustainability across Colliers. 'Sustainability is a reflection of our values in action, and a pathway to long-term resilience,' said Lagrasta. 'Built to Last reflects where we are today – and more importantly, where we're going. I'm energized by our people's passion and proud to help lead this next chapter of impact.' The full 2024 Global Sustainability Report is available at About Colliers Colliers (NASDAQ, TSX: CIGI) is a global diversified professional services and investment management company. Operating through three industry-leading platforms – Real Estate Services, Engineering, and Investment Management – we have a proven business model, an enterprising culture, and a unique partnership philosophy that drives growth and value creation. For 30 years, Colliers has consistently delivered approximately 20% compound annual returns for shareholders, fueled by visionary leadership, significant inside ownership and substantial recurring earnings. With nearly $5.0 billion in annual revenues, a team of 23,000 professionals, and more than $100 billion in assets under management, Colliers remains committed to accelerating the success of our clients, investors, and people worldwide. Learn more at X @Colliers or LinkedIn. Media Contact Andrea CheungSenior Manager, Global Integrated Communications+1 416 324 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
